Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
Belatacept is employed alongside calcineurin inhibitor (CNI) therapy to prevent graft rejection in kidney transplant patients who are Epstein-Barr virus (EBV) seropositive. Preliminary data ...